EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access

Efficacy and safety of levamisole in childhood nephrotic syndrome

Girish Chandra Bhatt, Bhupeshwari Patel, Rashmi Ranjan Das, Shikha Malik, Martin Bitzan, Nihar Ranjan Mishra

Indian Journal of Pharmacology · 2023

DOI: 10.4103/ijp.ijp_673_21 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Indian Journal of Pharmacology, 2023. Verfasst von Girish Chandra Bhatt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Nephrology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Nephrotic Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Present evidence regarding the efficacy and safety of levamisole in childhood nephrotic syndrome (NS), particularly the steroid-sensitive NS (SSNS), is limited. We searched relevant databases such as PubMed/MEDLINE, Embase, Google Scholar, and Cochrane CENTRAL till June 30, 2020. We included 12 studies for evidence synthesis (5 were clinical trials that included 326 children). The proportion of children without relapses at 6–12 months was higher in the levamisole group as compared to steroids (relative risk [RR]: 5.9 [95% Confidence interval (CI): 0.13–264.8], I 2 = 85%). Levamisole as compared to the control increased the proportion of children without relapses at 6–12 months (RR: 3.55 [95% CI: 2.19–5.75], I 2 = 0%). The GRADE evidence was of “very-low certainty” except for the comparison of levamisole with control, the latter being of “moderate certainty.” To conclude, levamisole given to children with SSNS is beneficial in preventing relapses and achieving remission as compared to placebo or low-dose steroids. Good-quality trials are needed to provide a robust evidence in this regard. PROSPERO Registration number: CRD42018086247.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephrotic SyndromeChildHumansImmunosuppressive AgentsLevamisoleRecurrence

Stichwörter der Autor:innen

Evidence-based medicinelevamisolenephrotic syndromesystematic review

Substanzen

Immunosuppressive AgentsLevamisole

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Nephrology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
  • Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • McGill University Health Centre, Montreal, Canada; Department of Pediatrics, Kidney Centre of Excellence, Al Jalila Children's Hospital, Dubai, United Arab Emirates.
  • Department of Pediatrics, All India Institute of Medical Sciences, Kalyani, West Bengal, India.

Zitieren

APA

Bhatt, G. C., Patel, B., Das, R. R., Malik, S., Bitzan, M., & Mishra, N. R. (2023). Efficacy and safety of levamisole in childhood nephrotic syndrome. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_673_21

Vancouver

Bhatt GC, Patel B, Das RR, Malik S, Bitzan M, Mishra NR. Efficacy and safety of levamisole in childhood nephrotic syndrome. Indian Journal of Pharmacology. 2023. doi:10.4103/ijp.ijp_673_21

BibTeX
@article{Bhatt2023,
  author = {Bhatt, Girish Chandra and Patel, Bhupeshwari and Das, Rashmi Ranjan and Malik, Shikha and Bitzan, Martin and Mishra, Nihar Ranjan},
  title = {Efficacy and safety of levamisole in childhood nephrotic syndrome},
  journal = {Indian Journal of Pharmacology},
  year = {2023},
  doi = {10.4103/ijp.ijp_673_21}
}
Kostenlos starten →